BeiGene, Ltd. 688235.SS Stock
BeiGene, Ltd. Price Chart
BeiGene, Ltd. 688235.SS Financial and Trading Overview
BeiGene, Ltd. stock price | 125.09 CNY |
Previous Close | 112.3 CNY |
Open | 118.1 CNY |
Bid | 117.41 CNY x N/A |
Ask | 117.42 CNY x N/A |
Day's Range | 117.1 - 120.99 CNY |
52 Week Range | 82.26 - 170.49 CNY |
Volume | 5.91M CNY |
Avg. Volume | 2.05M CNY |
Market Cap | 147.06B CNY |
Beta (5Y Monthly) | 0.786619 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.71 CNY |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 187.91 CNY |
688235.SS Valuation Measures
Enterprise Value | 8.38B CNY |
Trailing P/E | N/A |
Forward P/E | -19.901693 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 94.44677 |
Price/Book (mrq) | 2.9421198 |
Enterprise Value/Revenue | 5.379 |
Enterprise Value/EBITDA | -5.08 |
Trading Information
BeiGene, Ltd. Stock Price History
Beta (5Y Monthly) | 0.786619 |
52-Week Change | 19.48% |
S&P500 52-Week Change | 20.43% |
52 Week High | 170.49 CNY |
52 Week Low | 82.26 CNY |
50-Day Moving Average | 146.71 CNY |
200-Day Moving Average | 131.32 CNY |
688235.SS Share Statistics
Avg. Volume (3 month) | 2.05M CNY |
Avg. Daily Volume (10-Days) | 2.93M CNY |
Shares Outstanding | 115.06M |
Float | 57.08M |
Short Ratio | N/A |
% Held by Insiders | 10.71% |
% Held by Institutions | 15.57% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -123.11% |
Operating Margin (ttm) | -110.36% |
Gross Margin | -26.017% |
EBITDA Margin | -105.88% |
Management Effectiveness
Return on Assets (ttm) | -15.36% |
Return on Equity (ttm) | -38.17% |
Income Statement
Revenue (ttm) | 1.56B CNY |
Revenue Per Share (ttm) | 15.04 CNY |
Quarterly Revenue Growth (yoy) | 46.00% |
Gross Profit (ttm) | -511062000 CNY |
EBITDA | -1648758016 CNY |
Net Income Avi to Common (ttm) | -1917048064 CNY |
Diluted EPS (ttm) | -8.44 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 3.87B CNY |
Total Cash Per Share (mrq) | 37.13 CNY |
Total Debt (mrq) | 545.19M CNY |
Total Debt/Equity (mrq) | 13.11 CNY |
Current Ratio (mrq) | 3.75 |
Book Value Per Share (mrq) | 39.91 |
Cash Flow Statement
Operating Cash Flow (ttm) | -1823832960 CNY |
Levered Free Cash Flow (ttm) | -1309241344 CNY |
Profile of BeiGene, Ltd.
Country | China |
State | N/A |
City | Grand Cayman |
Address | 94 Solaris Avenue |
ZIP | KY1-1108 |
Phone | 345-949 4123 |
Website | https://www.beigene.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 9400 |
BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Enlivex Therapeutics Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
Q&A For BeiGene, Ltd. Stock
What is a current 688235.SS stock price?
BeiGene, Ltd. 688235.SS stock price today per share is 125.09 CNY.
How to purchase BeiGene, Ltd. stock?
You can buy 688235.SS shares on the Shanghai exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BeiGene, Ltd.?
The stock symbol or ticker of BeiGene, Ltd. is 688235.SS.
Which industry does the BeiGene, Ltd. company belong to?
The BeiGene, Ltd. industry is Biotechnology.
How many shares does BeiGene, Ltd. have in circulation?
The max supply of BeiGene, Ltd. shares is 901.03M.
What is BeiGene, Ltd. Price to Earnings Ratio (PE Ratio)?
BeiGene, Ltd. PE Ratio is now.
What was BeiGene, Ltd. earnings per share over the trailing 12 months (TTM)?
BeiGene, Ltd. EPS is -4.71 CNY over the trailing 12 months.
Which sector does the BeiGene, Ltd. company belong to?
The BeiGene, Ltd. sector is Healthcare.
Stocks Related By Sector
Stocks Related By Industry
- Chongqing Zhifei Biological Products Co., Ltd. 300122.SZ Stock
- Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. 603392.SS Stock
- Beijing Tiantan Biological Products Co., Ltd. 600161.SS Stock
- Shanghai RAAS Blood Products Co., Ltd. 002252.SZ Stock
- Hualan Biological Engineering Inc. 002007.SZ Stock